This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
by Zacks Equity Research
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?
by Zacks Equity Research
In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024
by Zacks Equity Research
RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
by Ahan Chakraborty
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
by Zacks Equity Research
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
by Zacks Equity Research
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Regeneron Gains 13.5% Year to date: How to Play the Stock?
by Zacks Equity Research
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
by Kinjel Shah
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research site in Indiana.
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
by Zacks Equity Research
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.